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Immunomonitoring Tumor-Specific T Cells in Delayed-
Type Hypersensitivity Skin Biopsies After Dendritic Cell
Vaccination Correlates With Clinical Outcome
I. Jolanda M. de Vries, Monique R. Bernsen, W. Joost Lesterhuis, Nicole M. Scharenborg, Simon P. Strijk,
Marie-Jeanne P. Gerritsen, Dirk J. Ruiter, Carl G. Figdor, Cornelis J.A. Punt, and Gosse J. Adema
A B S T R A C T
Purpose
Tumor-specific immunomonitoring is essential to evaluate the efficacy of vaccination against
cancer. In this study, we investigated the predictive value of the presence or absence of
antigen-specific T cells in biopsies from delayed-type hypersensitivity (DTH) sites.
Patients and Methods
In our ongoing clinical trials, HLA-A2.1 melanoma patients were vaccinated with mature
dendritic cells (DC) pulsed with melanoma-associated peptides (gp100 and tyrosinase) and
keyhole limpet hemocyanin.
Results
After intradermal administration of a DTH challenge with gp100- and tyrosinase peptide–
loaded DC, essentially all patients showed a positive induration. In clinically responding
patients, T cells specific for the antigen preferentially accumulated in the DTH site, as
visualized by in situ tetramer staining. Furthermore, significant numbers of functional gp100
and tyrosinase tetramer–positive T cells could be isolated from these DTH biopsies, in
accordance with the applied antigen in the DTH challenge. We observed a direct correlation
between the presence of DC vaccine–related T cells in the DTH biopsies of stage IV
melanoma patients and a positive clinical outcome (P  .0012).
Conclusion
These findings demonstrate the potency of this novel approach in the monitoring of
vaccination studies in cancer patients.
J Clin Oncol 23:5779-5787. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Dendritic cell (DC) vaccines have been suc-
cessfully used for the induction of antitumor
T-cell reactivity in melanoma patients.1,2
These early trials have shown that vaccina-
tion withDC is feasible, nontoxic, and effec-
tive in some patients, provided that the DC
are appropriately matured and activated.3-8
To exploit the full potential of these immu-
nostimulatory cells, many questions need to
be answered.9 These questions can only be
properly addressed in clinical trials. Be-
sides clinical end points, it is of utmost
importance to monitor the immune reac-
tivity during therapy.
Most immunologic monitoring assays
for antigen-specific cytotoxic T lymphocytes
(CTL) in peripheral blood in vaccinated pa-
tients depended on their ability to prolifer-
ate extensively and acquire lytic activity or to
release relatively large amounts of cytokines
in vitro.10,11 The development of fluorescent
major histocompatibility complex (MHC)/
peptide tetramers has greatly improved the
ability to detect tumor antigen–specific T
cells.12 This method has proven useful for
identifying T-cell responses in peripheral
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blood to peptide-based vaccines.10 Additional bioassays,
like cytotoxicity assays, or secretion of cytokines, such as
interferon gamma (IFN-), are essential to measure the
functional properties of antigen-specific CTL.13,14 Indeed,
tetramer-positive T cells in cancer patients have been de-
scribed that are functionally ineffective in lysing target cells
or producing cytokines.15 Therefore, analysis of both fre-
quency and functionality of natural or vaccine-induced
CTL is preferred.
Anothermajor question is the optimal compartment in
which vaccine-related immune responses should be moni-
tored. Romero et al16 described high numbers of MHC/
peptide tetramer–positive cells in tumor-infiltrated lymph
nodes. Unfortunately, lymph nodes and the tumor site itself
are not readily available for monitoring purposes. In this
study, we tested the hypothesis that skin biopsies taken
from delayed-type hypersensitivity (DTH) reactions are an
optimal compartment for immunomonitoring purposes.
PATIENTS AND METHODS
Antibodies, MHC Tetramers, and Immunostaining
Flow cytometry was performed using fluorescein isothiocya-
nate–conjugated (anti-HLA class I [W6/32]17 and anti-HLA
DR/DP [Q5/13]18) and phyco erytrin–conjugated monoclonal
antibodies (anti-CD80, Becton Dickinson, Mountain View, CA;
anti-CD14 and anti-CD83, Beckman Coulter, Mijdrecht, the Neth-
erlands; and anti-CD86, Pharmingen, San Diego, CA). Immunohis-
tochemical analysis was performed with monoclonal antibodies
purchased from Pharmingen. Tetrameric MHC-peptide complexes
(HLA-A2.1-gp100:154-162, HLA-A2.1-gp100:280-288, HLA-A2.1-
tyrosinase:369-377, HLA-A2.1-MART-1(ELAGIGILTV), HLA-
A2.1-HIVgag (SLYNTVATL), andHLA-A2.1-CMV(GLCTLVAML)
were provided by H. Spits (Netherlands Cancer Institute, Amster-
dam, the Netherlands) or purchased from Immunomics, Beckman
Coulter Inc (San Diego, CA).
Patients
Melanoma patients (stage III and IV according to American
Joint Committee on Cancer criteria19) who are participating in
ongoing protocols in which the immune responses of DC vaccines
are studied were included.6 Eligibility criteria included HLA-A2.1
phenotype, HLA-DR4 phenotype (when also MHC class II bind-
ing peptides were used), melanoma expressing gp100 and tyrosi-
nase, andWHOperformance status of 0 or 1. Additional eligibility
criteria for stage IV patients included the following: documented
progressive disease within 2 months before study entry, serum
lactate dehydrogenase  2 the upper limit of normal, no prior
chemotherapy or immunotherapy within 3 months before study
entry, and no residual toxicity from prior treatments. For stage III
patients, further eligibility criteria included planned radical lymph
node resection and no prior chemotherapy, radiotherapy, or immu-
notherapy. Patients with brain metastases, serious concomitant dis-
ease, or clinical signs of a history of a second malignancy were
excluded. The studieswere approved by the local regulatory commit-
tee, and written informed consent was obtained from all patients.
Patients received the DC vaccine according to different study
protocols as listed in Table 1. All patients who remained free of
disease progression after the first vaccination cyclewere eligible for
two maintenance cycles at 6-month intervals, each consisting of
three biweekly intranodal vaccinations in a clinically tumor-free
lymph node region under ultrasound guidance with mature DC
and alternately pulsed with wild-type or modified gp100 and ty-
rosinase peptides and keyhole limpet hemocyanin (KLH). Nine
patients received twomaintenance cycles, and 17 patients received
one maintenance cycle.
A clinical responsewas defined as stable disease formore than
4 months or any partial or complete response. Responses were
defined according to Response Evaluation Criteria in Solid Tu-
mors.20 Toxicity was assessed according to National Cancer Insti-
tute Common Toxicity Criteria. Progression-free survival was
calculated from the day of the first vaccination. Patients were
Table 1. Immune Responses and DTH According to Treatment Schedule and Disease Status
Disease Treatment Schedule
KLH Responses
in Blood (No. of
patients positive/
No. tested) DTH Reactivity and DIL Outgrowth
Group
No. Stage
No. of
Patients Peptides Route
No. of
Vaccinations IL-2 T Cells Abs
Induration
(No. of patients
positive/No.
tested)
Mean
( 106 cells)
Range
( 106 cells)
1 IV 10 Class I wt† IV/ID 3  9/10 9/10 9/9 0.9 0-1.5
2 IV 10 Class I mod‡ IV/ID 3  9/9 6/10 8/10 0.4 0-2.6
3 IV 6 Class I wt/class II IN§ 3  6/6 4/5 6/6 0.4 0-2.0
4 III 7 Class I wt ID 4  5/5 5/6 6/7 1.4 0-4.4
5 III 6 Class I wt IN 4  5/5 6/6 6/6 3.1 0-6.7
Abbreviations: KLH, keyhole limpet hemocyanin; DTH, delayed-type hypersensitivity; DIL, DTH-infiltrated lymphocytes; IL-2, interleukin 2; Abs, immuno-
globulin G antibodies against KLH; wt, wild types; mod, modified; IV, intravenous; ID, intradermal; IN, intranodal.
Injections were followed by systemic low-dose IL-2 (3 to 6 mU subcutaneously).
†Class I wt: HLA class I–restricted wild-type gp100-derived peptides 154-167 and 280-288 and HLA class I–restricted wild-type tyrosinase-derived peptide 369-376.
‡Class I mod: HLA class I–restricted modified gp100-derived peptides 154-167 Q3A and 280-288 A3V and HLA class I–restricted wild-type
tyrosinase-derived peptide 369-376.
§IN injections were performed under ultrasound guidance.
Class II: HLA class II–restricted gp100-derived peptide 44-59 and tyrosinase-derived peptide 448-462 analog.
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evaluated for response after completing the vaccinations and every
3 months thereafter.
DC Preparation and Characterization
KLH-loaded DC were generated from peripheral-blood
mononuclear cells (PBMC) and matured with autologous
monocyte-conditioned medium with prostaglandin E2 (10 g/
mL; Pharmacia & Upjohn, Puurs, Belgium) and 10 ng/mL of
recombinant tumor necrosis factor alpha (provided by Dr G.
Adolf, Bender Wien, Vienna, Austria), as described previous-
ly.21,22 This procedure gave rise to mature DCmeeting the release
criteria described previously.9
Peptide Pulsing
DCwere pulsed with the HLA class I gp100-derived peptides
gp100:154-167 (wild type ormodifiedQ3A), and gp100:280-288
(wild type or modified A3V) and the tyrosinase-derived peptide
tyrosinase:369-376.23-25 DC from HLA-DR4–positive patients
were also pulsed with HLA-DR4–binding peptides of both gp100
and tyrosinase (gp100:44-59 and tyro:448-462 analog; both pro-
vided byD. Schadendorf, Department of Dermatology, University
Hospital Mannheim, Mannheim, Germany).26,27 Peptide pulsing
was performed as described previously, and cells were resus-
pended in 0.1 mL for intradermal (ID) or intranodal injection.6
DTH
One to 2 weeks after a vaccination cycle consisting of three or
four DC vaccinations, a DTH skin test was performed. Briefly,
unpulsed DC, DC pulsed with the indicated peptides, DC pulsed
with KLH, andDCpulsed with the indicated peptides plus KLH (2
to 10 105DC each)were injected ID in the skin of the back of the
patients at four different sites. The maximum diameter of indura-
tion was measured after 48 hours.
From positive DTH sites ( 2 mm), punch biopsies (6 mm)
were obtained and cut in half; one part was cryopreserved, and the
other part was cut in pieces. Leukocytes emigrating from these
tissue pieces were cultured in RPMI 1640/7% human serum sup-
plemented with interleukin (IL) -2 (100 U/mL). Every 7 days, half
of the medium was replaced by fresh IL-2–containing RPMI
1640/7% HS. After 2 to 4 weeks of culturing, T cells were tested.
In Situ Staining With Tetramer
From cryopreserved DTH biopsies, 8-m thick cryosections
were cut. Tissue sections were fixed with 4% paraformaldehyde (3
minutes), and nonspecific protein binding was prevented by using
20% normal goat serum in phosphate-buffered saline (PBS; 20
minutes). Incubation with tetramer (5 mol/L, 5% normal goat
serum in PBS) was performed overnight at 4°C in the absence or
presence of CD8 (2g/mL,WT82). After washing in PBS, sections
were fixedwith 4%paraformaldehyde (20minutes) and incubated
with polyclonal rabbit serum against streptavidine (1:800; Rock-
land Inc, Gilbertsville, PA). The specific binding of tetramer was
visualized using a polyclonal goat-antirabbit-Alexa594 (1:500, 30
minutes, room temperature [RT]; Molecular Probes, Europe BV,
Leiden, the Netherlands), resulting in a red fluorescent signal.
CD8 was visualized using a polyclonal goat-antimouse-Alexa498
(1:500, 30 minutes, RT; Molecular Probes), resulting in a green
fluorescent signal. Sections were counterstained with 4,6-
diamidino-2-phenylindole, resulting in blue fluorescent nuclei.
MHC Tetramer Staining
DTH-derived cells (1 105 cells in 10L) or PBMC (1 106
cells in 10 L) were incubated with phyco erytrin–labeled
tetrameric-MHC complexes for 1 hour at RT. In the last 20 min-
utes of this incubation, fluorescein isothiocyanate–conjugated
monoclonal antibodies directed against either CD4 or CD8 (both
Becton Dickinson) were added. After washing, the samples were
analyzed by flow cytometry.
Cytotoxicity Assay and Cytokine Production
Cytotoxic activity and production of cytokines by DTH-
derived cells in response to T2 cells pulsed with the indicated
peptides or BLM (a melanoma cell line expressing HLA-A2.1 and
no endogenous expression of gp100 and tyrosinase), transfected
with control antigen G250, or with gp100 or an allogenic HLA-
A2.1-positive, gp100-positive, and tyrosinase-positive tumor cell
line (MEL624) were measured. Cytotoxic activity of DTH-
infiltrated lymphocytes (DIL) was measured using the chromium
release assay.28 Cytokine production was measured in superna-
tants after 16 hours of coculture by the cytometric bead array
(Th1/Th2 Cytokine CBA 1; BD Pharmingen).
Statistics
Statistical significance was evaluated using the log-rank test.
Statistical analysis was performed with SPSS 11.0 for Windows
(SPSS Inc, Chicago, IL).
RESULTS
DC-Based Vaccination of Melanoma Patients
In total, 39melanomapatients were treatedwith tumor
peptide and KLH-loaded DC (Table 1). Most patients
mounted a potent proliferative (35 of 36 patients tested)
and antibody (30 of 37 patients tested) response against
KLH (Table 1). The proliferative anti-KLH response was
already detected after one DC vaccination (Fig 1). These
results demonstrate that the mature DC used were able to
mount a de novo immune response.
Fig 1. Keyhole limpet hemocyanin (KLH) –specific proliferation of
peripheral-blood mononuclear cells (PBMC) and delayed-type hypersensitivi-
ty–infiltrated lymphocytes (DIL) after dendritic cell vaccination. Proliferative
response against KLH in the PBMC (filled bars) and DIL cultures (hatched
bars) of a vaccinated patient (group 1; Table 1) is shown.
DTH T Cells Correlate With Clinical Outcome
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Induration at the DTH Is Not Predictive of a
Vaccine-Induced Immune Response
To investigate the immune response generated in the
vaccinated patients, DTH challenges were performed with
mature DC. In most patients (35 of 38 patients tested),
positive DTH reactions with indurations up to 33mmwere
observed. However, both unloadedDC andDCpulsed with
KLHand/or peptidesmounted a positiveDTH (Fig 2A).No
correlation was observed between the induration size and
the type of injected antigen (data not shown). Therefore, in
our setting, the induration at the DTH site was not predic-
tive for vaccine-induced immune responses.
DTH: Immunohistochemistry, T-Cell Outgrowth,
and Detection of KLH-Specific T Cells
Infiltrating cell clusters were observed in biopsies taken
from DTH sites of peptide- and/or KLH-loaded and
-unloaded DC but not in control skin biopsies (Fig 2). The
majority of cells (90%) in these clusters were CD2 and
CD3T lymphocytes (15 biopsies of five patients). Approx-
imately 50% to 70% of the cells were CD4, and 30% to
50%wereCD8T cells (Fig 2).Only a fewCD16 cells were
found scattered between the T-cell clusters, and no CD20,
CD23 (B lymphocytes), or CD56 (natural killer) cells
were discerned (data not shown).
Fig 2. Analyses of delayed-type hyper-
sensitivity (DTH) biopsies in situ. Staining
of the DTH sections of a vaccinated patient
(group 4; Table 1) revealed infiltrating clus-
ters of (A) CD8 and (B) CD4 T cells. In situ
tetramer staining on cryosections of biop-
sies: sections were stained with CD8 in
green (C and E) in combination with tetramer
tyrosinase (D) or gp100:280 (F) in red. All
sections (A through F) were counterstained
with 4,6-diamidino-2-phenylindole, resulting
in blue fluorescent nuclei.
de Vries et al
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Leukocytes from DTH biopsies were further character-
ized after culture with low amounts of IL-2 without the addi-
tion of antigen. Outgrowth of DIL occurred in 70% of the
biopsies induced by antigen-loaded DC (32 patients) and in
only 55% of the biopsies induced by unloaded DC. DIL were
mainly T cells, and their amount varied between biopsies (Ta-
ble 1). The rates of CD4 and CD8 T cells derived fromDIL
cultures varied among DIL cultures and between patients
(65% 21%CD4 and 27% 20%CD8). No correlation
was observed between the amount of T-cell outgrowth, the
induration, and the presence of KLH. Interestingly, functional
analysis of DIL from KLH-pulsed DC demonstrated a KLH-
specific response (Fig 1). No anti-KLH response was detected
in DIL from a DTH site injected with unpulsed DC (data not
shown). Thus, KLH-reactive T cells were specifically detected
in DTH sites injected with KLH-loaded DC, and positive in-
duration was not predictive for T-cell reactivity.
DTH: Detection of gp100- and Tyrosinase-
Specific T Cells
To determine the potential of DIL as a source for im-
munomonitoring of gp100- and tyrosinase-specific CD8
T cells, we performed tetramer stainings, the cytokine bead
array, or cytotoxicity assays. In 11 (six stage III patients and
five stage IV patients) of 22 patients tested, one or more
tetramer-positive T-cell population was readily detected
after one DC vaccination cycle in biopsies from DTH per-
formed with peptide-loaded DC (Fig 3, Table 2). In five
additional patients, antigen-specific CTL in DIL cultures
were detected after additional vaccination cycles (Table 2).
No tetramer-positive T cells were detected in DTH biopsies
injected with unloaded DC (n  4) or KLH-loaded DC
(n  3; Fig 3). Because significant numbers (up to 45% of
total T cells) of tetramer-positive T cells were present in the
cultured DTH biopsies (Table 2), we also analyzed the
presence of tetramer-positive T cells directly in blood at the
same time point. Strikingly, in six of seven patients, no
tetramer-positive cells were found in their PBMC, whereas in
five of these six patients, T-cell staining with two different
tetramers was readily detected in their DIL cultures. In only
one of seven patients, aminor amount of gp100:154 tetramer-
positive (0.1%) and tyrosinase:369 tetramer-positive (0.03%)
T cells was detected in peripheral blood.
In 15 patients, sufficient DIL were available to determine
their cytokine production on coculture with peptide-loaded
target cells as well. In nine of 15 patients (27 biopsies), specific
cytokine release was detected (Fig 4, Table 2). Moreover, DIL
fromfivepatients produced cytokines on coculturewith target
cells endogenously expressing the tyrosinase or gp100 protein
(Fig 4). Especially large amounts of IFN- and IL-2 were pro-
duced, and in some cultures, IL-5, but not IL-4 or IL-10, was
detected. Importantly, the observed cytokine production by
DILcorrelatedwith thepresenceandspecificityof the tetramer
reactivity of the DIL (Fig 3).
Finally,DIL of 23 biopsies from10patientswere available
todetermine their cytotoxicity. SixDILcultures (fourpatients)
efficiently lysed peptide-loaded HLA-A2.1–positive target
cells. Again, the observed cytotoxicity corresponded with the
presence and specificity of the tetramer reactivity of the DIL
(Figs 5A to 5C). Collectively, these data demonstrate that sig-
nificant numbers of tetramer-positive T cells accumulated at
theDTHsiteandthat theseTcells specificallyproducedcytokines
andwere cytotoxic for tumor antigen–expressing target cells.
Fig 3. In delayed-type hypersensitivity (DTH) -infiltrated lymphocytes (DIL),
dendritic cells (DC)  keyhole limpet hemocyanin (KLH), no tetramer-
positive T cells were observed (A to C). In the same patient (group 4, see
Table 1), positivity for all three tetramers was observed in DTH: DC  three
peptides (D to F). In DIL from DTH, DC  KLH  three peptides, positivity
for two tetramers were observed (G to I). PE, phyco erytrin.
Table 2. Summary of Immunomonitoring Data of Positive DIL Cultures
Measure
Epitope
gp100:154 gp100:280 tyrosinase:369
Tetramer
Mean, % 2.6 7.3 3.3
Range, % 0.1-20.0 0.1-45.0 0.6-10.9
No. positive† 28 11 9
IFN-
Mean, pg/mL‡ 3776 1,707 3,375
Range, pg/mL 480- 10,000 427- 5,000 443- 10,000
No. positive† 16 16 15
Abbreviations: DIL, delayed-type hypersensitivity–infiltrated lympho-
cytes; IFN-, interferon gamma.
Mean of the positive tetramer DIL.
†Not all assays performed on every DIL culture
‡Mean of IFN- production of the positive DIL.
DTH T Cells Correlate With Clinical Outcome
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Detection of gp100- and Tyrosinase-Specific T
Cells in Single-Antigen DTH Reactions
To further discriminate the specific T-cell reactivity in
the DTH sites, DTH reactions were induced with mature
DC pulsed either with the gp100 peptides or the tyrosinase
peptide with or without KLH. Both tetramer and functional
analysis demonstrated that the specificity of the accumu-
lated T cells corresponded with the peptide loaded on the
injected DC (Fig 5). DIL derived from gp100 peptide–in-
duced DTH sites (47 tested, 20 positive) were specific for
gp100 and did not recognize tyrosinase and vice versa (47
tested, 10 positive). These data provide further support for
the hypothesis that CD8T cells accumulate atDTH sites in
accordance with the specificity of the DTH challenge.
In Situ Tetramer Analysis of DTH Biopsies
Weperformed in situ tetramer analysis on cryosections
of the biopsies to exclude the possibility that the observed
T-cell reactivity was induced in vitro. Tetramer-positive
cells were clearly detected with the gp100 or tyrosinase
tetramers but not with control tetramers (21 biopsies of
nine patients). Interestingly, the tetramer-positive cells
were specifically present in T-cell clusters (Figs 2C to 2F),
and their specificity fully correlated with the specificity of
the peptide loaded on the injected DC. No gp100 or tyrosi-
nase tetramer–positive cells were detected in unloaded
(n  3) and KLH-loaded (n  3) DTH biopsies. CD8
double staining further demonstrated that most of the
tetramer-positive T cells expressed CD8.
Fig 4. The delayed-type hypersensitivity
(DTH) –infiltrated lymphocytes (DIL) of which
the tetramer staining is depicted in Figure 3
was also tested for cytokine production.
Dendritic cells (DC) three peptides (A to C
and G to I); DTH: DC loaded  keyhole
limpet hemocyanin (KLH)  three peptides
(D to F and J to L). DIL cultures did not
recoginze control BLM-G250 (G, J) whereas
BLM-gp100 was recognized (H, K). Both DIL
cultures recognized MEL624, a melanoma
cell line expressing gp100 and tyrosinase
(I, L). IL, interleukin; TNF-, tumor necrosis
factor alpha; IFN-, interferon gamma.
de Vries et al
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In 71% of the patients exhibiting a positive staining in
situ (one half of the biopsy), the specificity correlated with
the specificity in the DIL cultures derived from the other
half of the biopsy. These findings demonstrate that the
antigen-specific T-cell reactivity reflects the in vivo situa-
tion and is not artificially induced by in vitro cultures.
Correlation With Clinical Outcome
To correlate the presence or absence of vaccine-related
T-cell responses and clinical outcome, patients were evalu-
ated for clinical response according to Response Evaluation
Criteria in Solid Tumors.20 Of 26 stage IV melanoma pa-
tients, 15 had progressive disease, 10 showed stable disease
of at least 4 months in duration, and one patient with
multiple liver metastases showed a complete remission.
One of the patients with stable disease had salvage surgery
and is now disease free at 52months.
No tumor-reactive DIL were observed in 13 of 15 pa-
tients with progressive disease (Fig 6). In six of 10 patients
with stable disease or better, vaccine-related T-cell re-
sponses were observed in their DIL, including one patient
with a complete response (Fig 6). The median progression-
free survival time of these six patients was 30 months
(range, 4 to 52 months). For comparison, in the six pa-
tients with stable disease without tumor-reactive DIL, the
median progression-free survival time was 6 months
(range, 4 to 11 months). The median progression-free sur-
vival times of stage IV patients with and without tumor-
reactive DIL were 17 and 2 months, respectively. Although
the number of patients was limited, this difference was
highly statistically significant (P .0012; Fig 6).
We further noted that, in all stage III melanoma
patients tested (10 of 13 patients), a specific T-cell re-
sponse was readily detected in their DIL. However, because
long-term follow-up is required for these patients, no correla-
tion between clinical outcome and the presence or absence
of tumor-reactive DIL can be made for this patient group at
this time.
DISCUSSION
Immunomonitoring is an essential step in the development
of evidence-based immunotherapy. In this study, we report
that sampling of DTH sites is an effective novel approach to
detect vaccine-related T cells predictive for clinical out-
come. We demonstrated the following: antigen-specific T
cells specifically accumulated in the DTH and their speci-
ficity corresponded with the specificity of the DTH chal-
lenge; after a brief culture step, up to 45% of the CD8 cells
were antigen specific, produced cytokines, and demon-
strated cytotoxic activity towards antigen-positive target
cells; and the presence of antigen-specific T cells is predic-
tive for the clinical outcome (P .0012).
Fig 5. Specificity of the tetramers corresponds with the presense of
cytotoxic activity (patient group 5, see Table 1 [C, hatched bar: T2gp100:
154, open bar: T2tyrosinase:369, closed bar: T2irrelevant peptide]) and
cytokine production of delayed-type hypersensitivity (DTH) –infiltrated lym-
phocytes (DIL; F, I). (A to C): DTH: dendritic cells (DC) loaded  keyhole
limpet hemocyanin (KLH)  three peptides. In DIL (patient group 4, see
Table 1) from DC  KLH  gp100 peptides only T cells positive for gp100
tetramers were observed (D to F). Tyrosinase tetramer positivity was
observed in the DIL DC  tyrosinase peptide (G to I). IFN-, interferon
gamma; PE, phyco erytrin; Irr, irrelevant peptide; Tyro, tyrosinase epitope;
FITC, fluorescein isothiocyanate.
Fig 6. Correlation between the presence of specific T cells and clinical
outcome. Kaplan-Meier plot comparing the progression-free survival of stage IV
melanoma patients with (closed line) and without (hatched line) tumor-specific
T cells in their delayed-type hypersensitivity–infiltrated lymphocytes.
DTH T Cells Correlate With Clinical Outcome
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Prediction of clinical efficacy based on immunologic
monitoring is crucial for the rational design of cancer vac-
cination studies as well as for defining the correlates of
protection. Several vaccination studies in cancer patients
have reported T-cell responses in the peripheral blood but
usually in a minority of patients or only after prolonged
re-stimulation with antigen in culture.11,29-32 One ap-
proach to accumulate T cells in vivo is to provide a local
antigenic challenge bymeans of aDTH reaction.Measuring
the degree of induration on DTH has frequently been used
to assess vaccine-related immune responses. In some stud-
ies, a correlation with clinical outcome was reported,
whereas in other studies, a positive DTH reaction was not
predictive for a successful response to vaccination.1,2,33,34 In
our vaccination settings, the application of a DTH consist-
ing of mature DC with or without antigen induced local
indurations and erythema and was not predictive for the
presence of vaccine-related T cells. The reason for the DTH
response to unloadedDC is not clear but could be explained
by the vast amount of chemokines produced by mature
DC.22 However, this cannot be the sole explanation because
patients with a positive DTH reaction after DC vaccination
did not develop induration at the site of the first ID injec-
tion of up to 25-fold higher numbers of DC.
Antigen-specific T cells were readily detected in the
DTH biopsies, whereas at the same time, these T cells were
largely undetectable in blood. Antigenic stimulation of
blood lymphocytes at limiting dilution conditions, as de-
scribed byCoulie et al,11 demonstrated that antigen-specific
T cells were detected in blood at low frequencies in our
responding patients (range, 1.2 to 7.7 105 of the CD8
cells; three patients). Coulie et al11 also reported low T-cell
frequencies in blood and implied that even these low num-
bers of CTL in blood (5  105 of the total CD8 T cells)
correlatedwith the rejection of a large volume tumor. In our
study, the presence or absence of these T cells in the DTH
biopsies nicely correlated (P .0012) with the progression-
free survival of the stage IV melanoma patients. Part of the
explanation for this highly significant correlation might be
that the conditions to obtain vaccine-specific DIL are more
stringent. These specific cells have to migrate and prolifer-
ate in vivo, and this might select for high-quality CTL
capable of eradicating tumor in vivo. The explanation of
why induration atDTH sites per se is not a specific indicator
for the induction of vaccine-related responses in many
studies, including ours, remains unclear.We note that, after
vaccination, but not before vaccination, simply culturing
PBMC in the absence of antigen is sufficient to induce a low
level of proliferation in most patients. This finding might
indicate that vaccineswith potent immune-activating prop-
erties, likeDC, also induce a certain level of general immune
activation sufficient for nonspecific T-cell accumulation,
resulting in a positive DTH reaction. Detailed analysis of
short-term cultures of DIL generated from biopsies of vac-
cinated patients revealed that a KLH response was only
detectedwhenKLHwasused as a challenge, indicating specific
accumulation of KLH-reactive T cells. Moreover, gp100/
tyrosinase-specific CD8 T cells in the DIL cultures corre-
sponded with the DTH challenge (ie, gp100-specific T cells
were only found in biopsies of DTH sites induced by gp100
peptide–loadedDC). No tetramer-positive cells were detected
inT-cell culturesderived fromDTHsiteswithunloadedDCor
DC loaded with KLH without the peptides. In situ tetramer
staining further demonstrated that specific T cells, corre-
sponding with the DTH challenges, accumulated in vivo and,
thus, were not induced in vitro. The DIL cultures containing
tetramer-positive CTL were also functionally active because
they produced cytokines (predominantly IFN-) and induced
lysis of cells expressing the appropriate target antigen.
Specific accumulation of antigen-specific T cells requires
the presence of antigen, resulting in specific retention of these
T cells. Culturing biopsies from DTH sites unmasks the
specific response and, thus, provides a convenient and com-
prehensive approach to monitor vaccine-related immune
responses. Therefore, it will be interesting to apply this
approach to other vaccination strategies in which either no
correlation or a positive correlation between the degree of
induration (as in autologous tumor cell Bacille Calmette-
Guerin vaccination) and clinical outcome was observed.33
In our recent pilot study, tetramer-specific, IFN-–produc-
ing T cells were also detected after a DTH challenge with
peptides alone, thereby obviating the necessity to generate
DC in non-DC–based vaccination studies.
Collectively, biopsies from DTH sites after DC vacci-
nation represent a convenient approach to detect antigen-
specific T-cell responses that highly correlate with clinical
outcome in stage IV melanoma patients. Therefore, this
approach may be of great value for the rational design of
vaccination studies and development of cancer vaccines.
■ ■ ■
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